Abstract
The nationwide breast cancer screening programme in The Netherlands for women aged 50–69 started in 1989. In our study we assessed the occurrence and stage distribution of interval cancers in women screened during 1990–1993. Records of 0.84 million screened women were linked to the regional cancer registries yielding a follow-up of at least 2.5 years. Age-adjusted incidence rates and relative (proportionate) incidences per tumour size including ductal carcinoma in-situ were calculated for screen-detected and interval cancers, and cancers in not (yet) screened women, comparing them with published data from the UK regions North West and East Anglia. In total 1527 interval cancers were identified: 0.95 and 0.99 per 1000 woman-years of follow-up in the 2-year interval after initial and subsequent screens respectively. In the first year after initial screening interval cancers amounted to 27% (26% after subsequent screens) of underlying incidence, and in the second year to 52% (55%). Generally, interval cancers had a more favourable tumour size distribution than breast cancer in not (yet) screened women. The Dutch programme detected relatively less (favourable) invasive cancers in initial screens than the UK programme, whereas the number of interval cancers confirms UK findings. Measures should be considered to improve the detection of small invasive cancers and to reduce false-negative rates, even if this will lead to increasing referral rates.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Akker-van, Marle ME van den, Koning, HJ de, Boer, R & Maas, PJ van der (1999) Reduction in breast cancer mortality due to the introduction of mass screening in the Netherlands; comparison with the UK. J Med Screening 6: 30–34.
Boer, R, Koning, HJ de, Threlfall, A, Warmerdam, P, Street, A, Friedman, E & Woodman, C (1998) Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study. Br Med J 317: 376–379.
Brekelmans, CTM, Collette, HJA, Collette, C, Fracheboud, J & Waard, F de (1992) Breast cancer after a negative screen: follow-up of women participating in the DOM screening programme. Eur J Cancer 28A: 893–895.
Day, N, McCann, J, Camilleri-Ferrante, C, Britton, P, Hurst, G & Cush, S Duffy S on behalf of the Quality Assurance Management Group of the East Anglian Breast Screening Programme (1995) Monitoring interval cancers in breast screening programmes: the East Anglian experience. J Med Screening 2: 180–185.
Faux, AM, Richardson, DC, Lawrence, GM, Wheaton, ME & Wallis, MG (1997) Interval breast cancers in the NHS Breast Screening Programme: does the current definition exclude too many?. J Med Screening 4: 169–173.
Fracheboud, J, Koning, HJ de, Beemsterboer, PMM, Boer, R, Hendriks, JHCL, Verbeek, ALM, Ineveld, BM van, Bruyn, AE de & Maas, PJ van der (1998) Nation-wide breast cancer screening in the Netherlands: results of initial and subsequent screening 1990–1995. Int J Cancer 75: 694–698.
Garvican, L & Littlejohns, P (1996) An evaluation of the prevalent round of the breast screening programme in South East Thames, 1988–1993: achievement of quality standards and population impact. J Med Screening 3: 123–128.
Klemi, PJ, Toikkanen, S, Räsänen, O, Parvinen, I & Joensuu, H (1997) Mammography screening interval and the frequency of interval cancers in a population-based screening. Br J Cancer 75, (5) 762–766.
Koning, HJ de, Ineveld, BM van, Oortmarssen, GJ van, Haes, JCJM de, Collette, HJA, Hendriks, JHCL & Maas, PJ van der (1991) Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer 49: 531–537.
Koning, HJ de, Fracheboud, J, Boer, R, Verbeek, ALM, Collette, HJA, Hendriks, JHCL, Ineveld, BM van, Bruyn, AE & PJ, van der Maas (National Evaluation Team for Breast cancer screening) (1995a) Nation-wide breast cancer screening in the Netherlands: support for breast-cancer mortality reduction. Int J Cancer 60: 777–780.
Koning, HJ de, Boer, R, Warmerdam, PG, Beemsterboer, PMM & Maas, PJ van der (1995b) Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer screening trial. J Natl Cancer Inst 87: 1217–1223.
Moss, SM, Coleman, DA, Ellman, R, Chamberlain, J, Forrest, APM, Kirkpatrick, AE, Thomas, BA & Price, JL (1993) Interval cancers and sensitivity in the screening centres of the UK trial of early detection of breast cancer. Eur J Cancer 29A: 225–258.
Moss, SM, Michel, M, Patnick, J, Johns, L, Blanks, R & Chamberlain, J (1995) Results from the NHS breast screening programme 1990–1993. J Med Screening 2: 186–190.
Nab, HW, Voogd, AC, Crommelin, MA, Kluck, HM, Heijden, LH van der & Coebergh, JWW (1993) Breast cancer in south-east Netherlands, 1960–1989: trends in incidence and mortality. Eur J Cancer 29A: 1557–1560.
NETB – National Evaluation Team for Breast cancer screening (1995). National evaluation of breast cancer screening in the Netherlands (IV), Department of Public Health, Erasmus University Rotterdam (in Dutch): Rotterdam
NETB – National Evaluation Team for Breast cancer screening (1997). National evaluation of breast cancer screening in the Netherland (VI), Department of Public Health, Erasmus University Rotterdam (in Dutch, with summary in English): Rotterdam
NCR – Netherlands Cancer Registry (1992). Incidence of cancer in the Netherlands 1989, SIG Health Care Information: Utrecht
Oortmarssen, GJ van, Habbema, JDF, Maas, PJ van der, Koning, HJ de, Collette, HJA, Verbeek, ALM, Geerts, AT & Lubbe, KTN (1990) A model for breast cancer screening. Cancer 66: 1601–1612.
Peeters, PHM, Verbeek, ALM, Hendriks, JHCL, Holland, R, Mravunac, M & Vooijs, GP (1989) The occurrence of interval cancers in the Nijmegen screening programme. Br J Cancer 59: 929–932.
Prior, P, Woodman, CBJ, Wilson, S & Threlfall, AG (1996) Reliability of underlying incidence rates for estimating the effect and efficiency of screening for breast cancer. J Med Screening 3: 119–122.
Schouten, LJ, Rijke, JM de, Schlangen, JT & Verbeek, ALM (1998) Evaluation of the effect of breast cancer screening by record linkage with the cancer registry, the Netherlands. J Med Screening 5: 37–41.
Sylvester, PA, Davies, JD, Vipond, MN, Webb, AJ, Kutt, E & Farndon, JR (1997) A comparative audit of prevalent, incident and interval cancers in the Avon breast screening programme. Ann R Coll Surg Engl 79: 272–275.
Tabár, L, Faberberg, G, Day, NE & Holmberg, L (1987) What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two-county breast cancer screening trial. Br J Cancer 55: 547–551.
Vitak, B, Stål, O, Månson, JC, Thomas, BA, Arnesson, LG, Ekelund, L, Måre, K, Nordenskjöld, B, Källström, AC & Bång, H (1997) Interval cancers and cancers in non-attenders in the Östergötland mammographic screening programme. Duration between screening and diagnosis, S-phase fraction and distant recurrence. Eur J Cancer 33: 1453–1460.
Woodman, CBJ, Threlfall, AG, Boggis, CRM & Prior, P (1995) Is the three-year breast screening interval too long? Occurrence of interval cancers in NHS breast screening programme’s north western region. Br Med J 310: 224–226.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Fracheboud, J., Koning, H., Beemsterboer, P. et al. Interval cancers in the Dutch breast cancer screening programme. Br J Cancer 81, 912–917 (1999). https://doi.org/10.1038/sj.bjc.6690786
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690786
Keywords
This article is cited by
-
Interval cancer in the Córdoba Breast Tomosynthesis Screening Trial (CBTST): comparison of digital breast tomosynthesis plus digital mammography to digital mammography alone
European Radiology (2024)
-
Detection and interval cancer rates during the transition from screen-film to digital mammography in population-based screening
BMC Cancer (2018)
-
Aggressive primary treatments with favourable 5-year survival for screen-interval breast cancers
BMC Cancer (2018)
-
The epidemiology, radiology and biological characteristics of interval breast cancers in population mammography screening
npj Breast Cancer (2017)
-
Population-based screening for cancer: hope and hype
Nature Reviews Clinical Oncology (2016)